FDA Announces New Rare Disease Framework With Potential Implications for IP Strategy
Key Takeaway: On October 14, 2026, the FDA announced a proposed framework for rare disease drug development that aims to provide greater regulatory flexibility and disease-tailored evaluation. Increased regulatory clarity...
GSA’s New AI Clause Is Now in Effect: What AI Vendors and Investors Need to Know
Key Takeaways: The U.S. General Services Administration’s (GSA) new AI clause gives the government ownership of fine-tuned model weights and other custom developments built from government data under GSA large...
Aerospace Vertical Integration: Turning Manufacturing Control Into an IP Advantage
Key Takeaways: Vertical integration and in-house manufacturing can provide aerospace companies with greater control over supply chains and manufacturing capacity while creating new opportunities for innovation. To maximize the value...
Subscribe for News and Updates